The University of Western Australia
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1911-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.uwa.edu.au
Clinical Trials
72
Active:1
Completed:28
Trial Phases
5 Phases
Phase 1:2
Phase 2:6
Phase 3:6
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
Not Applicable
44 (65.7%)Phase 4
9 (13.4%)Phase 2
6 (9.0%)Phase 3
6 (9.0%)Phase 1
2 (3.0%)Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours
Recruiting
- Conditions
- Brain Tumours
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 100
- Registration Number
- NCT06951659
- Locations
- 🇦🇺
Sir Charles Gairdner Osborne Park Health Care Group, Perth, Western Australia, Australia
Treatable Traits in Interstitial Lung Disease
Not Applicable
Not yet recruiting
- Conditions
- Interstitial Lung Diseases (ILD)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 132
- Registration Number
- NCT06626438
- Locations
- 🇦🇺
Fiona Stanley Hospital, Perth, Washington, Australia
The Plastic Exposure Reduction Transforms Health (PERTH) Trial
Not Applicable
Recruiting
- Conditions
- InflammationEndocrine DisruptorsCardiometabolic Risk Factors
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 60
- Registration Number
- NCT06571994
- Locations
- 🇦🇺
Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
Not Applicable
Recruiting
- Conditions
- CancerMalignant Pleural EffusionRespiratory Disease
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 160
- Registration Number
- NCT04322136
- Locations
- 🇦🇺
Institute for Respiratory Health, Nedlands, Western Australia, Australia
Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury
Phase 1
Completed
- Conditions
- Spinal Cord Injuries
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 10
- Registration Number
- NCT03945110
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
ProGenis Pharmaceuticals Secures MTPConnect Funding for Novel RNA-Based Type 2 Diabetes Treatment
ProGenis Pharmaceuticals received funding from MTPConnect's TTRA program to advance PGP-011, a small RNA drug targeting insulin resistance in type 2 diabetes patients.